MedTrace Logo

Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia

NCT01217788 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2011-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.

Conditions

Interventions

DRUG

PH94B intranasal spray

Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray

Sponsors & Collaborators

  • Pherin Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael L Liebowitz, M.D. · Medical Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-02-28
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01217788 on ClinicalTrials.gov